JP2020533289A5

JP2020533289A5 -

Download PDF

Info

Publication number: JP2020533289A5
Authority: JP; Japan
Prior art keywords: cells; cell; combination; subject; antigen
Prior art date: 2018-09-06
Legal status : Pending

Application number

JP2020513340A

Other languages

English (en)

Japanese (ja)

Other versions

JP2020533289A (ja

Filing date

2018-09-06

Publication date

2021-10-21

2018-09-06 Application filed filed Critical

2018-09-06 Priority claimed from PCT/US2018/049812 external-priority patent/WO2019051135A1/en

2020-11-19 Publication of JP2020533289A publication Critical patent/JP2020533289A/ja

2021-10-21 Publication of JP2020533289A5 publication Critical patent/JP2020533289A5/ja

2022-12-13 Priority to JP2022198485A priority Critical patent/JP2023030005A/ja

Status Pending legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 claims description 249
210000004027 cell Anatomy 0.000 claims description 240
210000001744 T-lymphocyte Anatomy 0.000 claims description 168
108090000623 proteins and genes Proteins 0.000 claims description 142
230000027455 binding Effects 0.000 claims description 118
239000003795 chemical substances by application Substances 0.000 claims description 117
230000014509 gene expression Effects 0.000 claims description 111
239000000427 antigen Substances 0.000 claims description 106
108091007433 antigens Proteins 0.000 claims description 106
102000036639 antigens Human genes 0.000 claims description 106
210000002865 immune cell Anatomy 0.000 claims description 96
238000000034 method Methods 0.000 claims description 93
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 85
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 81
229960004397 cyclophosphamide Drugs 0.000 claims description 81
102000040430 polynucleotide Human genes 0.000 claims description 70
108091033319 polynucleotide Proteins 0.000 claims description 70
239000002157 polynucleotide Substances 0.000 claims description 70
201000010099 disease Diseases 0.000 claims description 68
108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 66
108091008874 T cell receptors Proteins 0.000 claims description 59
102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 59
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 59
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 58
229960001756 oxaliplatin Drugs 0.000 claims description 58
230000001506 immunosuppresive effect Effects 0.000 claims description 57
239000003112 inhibitor Substances 0.000 claims description 54
239000000203 mixture Substances 0.000 claims description 51
230000000694 effects Effects 0.000 claims description 46
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 41
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 41
210000001519 tissue Anatomy 0.000 claims description 40
108010074708 B7-H1 Antigen Proteins 0.000 claims description 38
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 38
239000012634 fragment Substances 0.000 claims description 35
101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 34
102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 34
239000002246 antineoplastic agent Substances 0.000 claims description 30
201000011510 cancer Diseases 0.000 claims description 30
-1 cyclophosphamide Chemical compound 0.000 claims description 30
230000001965 increasing effect Effects 0.000 claims description 30
210000003289 regulatory T cell Anatomy 0.000 claims description 30
229940127089 cytotoxic agent Drugs 0.000 claims description 28
102000004127 Cytokines Human genes 0.000 claims description 25
108090000695 Cytokines Proteins 0.000 claims description 25
239000012636 effector Substances 0.000 claims description 25
230000003834 intracellular effect Effects 0.000 claims description 19
230000035755 proliferation Effects 0.000 claims description 18
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 16
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 16
101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 16
230000028993 immune response Effects 0.000 claims description 15
230000011664 signaling Effects 0.000 claims description 15
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 14
101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 13
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 13
206010062016 Immunosuppression Diseases 0.000 claims description 13
102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 13
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 13
102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 12
101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 12
101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 12
102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 12
101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 11
206010039491 Sarcoma Diseases 0.000 claims description 11
102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 11
230000004807 localization Effects 0.000 claims description 11
101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 9
IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 9
239000002207 metabolite Substances 0.000 claims description 9
102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 8
108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 8
102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 8
229960000390 fludarabine Drugs 0.000 claims description 8
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 8
210000003071 memory t lymphocyte Anatomy 0.000 claims description 8
238000001959 radiotherapy Methods 0.000 claims description 8
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 7
102100024263 CD160 antigen Human genes 0.000 claims description 7
102100038078 CD276 antigen Human genes 0.000 claims description 7
101710185679 CD276 antigen Proteins 0.000 claims description 7
102100031351 Galectin-9 Human genes 0.000 claims description 7
101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 7
101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 7
101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 7
102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 7
101150065403 NECTIN2 gene Proteins 0.000 claims description 7
102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 7
102100035488 Nectin-2 Human genes 0.000 claims description 7
108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 7
102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 7
229960005305 adenosine Drugs 0.000 claims description 7
230000012010 growth Effects 0.000 claims description 7
238000009094 second-line therapy Methods 0.000 claims description 7
238000001356 surgical procedure Methods 0.000 claims description 7
102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 6
101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 6
101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
210000000130 stem cell Anatomy 0.000 claims description 6
102000004452 Arginase Human genes 0.000 claims description 5
108700024123 Arginases Proteins 0.000 claims description 5
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
102000003814 Interleukin-10 Human genes 0.000 claims description 5
108090000174 Interleukin-10 Proteins 0.000 claims description 5
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
229950009791 durvalumab Drugs 0.000 claims description 5
208000020816 lung neoplasm Diseases 0.000 claims description 5
229960003301 nivolumab Drugs 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
108010002350 Interleukin-2 Proteins 0.000 claims description 4
102000000588 Interleukin-2 Human genes 0.000 claims description 4
102000004388 Interleukin-4 Human genes 0.000 claims description 4
108090000978 Interleukin-4 Proteins 0.000 claims description 4
102100023123 Mucin-16 Human genes 0.000 claims description 4
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
230000009467 reduction Effects 0.000 claims description 4
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
101150083327 CCR2 gene Proteins 0.000 claims description 3
102100038077 CD226 antigen Human genes 0.000 claims description 3
101150013553 CD40 gene Proteins 0.000 claims description 3
101150077124 CXCL10 gene Proteins 0.000 claims description 3
101150009911 Ccl7 gene Proteins 0.000 claims description 3
101150074775 Csf1 gene Proteins 0.000 claims description 3
101150061021 Cxcr2 gene Proteins 0.000 claims description 3
101150034862 Gng7 gene Proteins 0.000 claims description 3
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 3
102100037850 Interferon gamma Human genes 0.000 claims description 3
108010074328 Interferon-gamma Proteins 0.000 claims description 3
102000013462 Interleukin-12 Human genes 0.000 claims description 3
108010065805 Interleukin-12 Proteins 0.000 claims description 3
102000003816 Interleukin-13 Human genes 0.000 claims description 3
108090000176 Interleukin-13 Proteins 0.000 claims description 3
102000003812 Interleukin-15 Human genes 0.000 claims description 3
102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
102100038081 Signal transducer CD24 Human genes 0.000 claims description 3
208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 3
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
230000001093 anti-cancer Effects 0.000 claims description 3
229960003852 atezolizumab Drugs 0.000 claims description 3
229950002916 avelumab Drugs 0.000 claims description 3
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
229960002621 pembrolizumab Drugs 0.000 claims description 3
208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 3
210000004881 tumor cell Anatomy 0.000 claims description 3
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 2
BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 2
102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 2
101150029707 ERBB2 gene Proteins 0.000 claims description 2
102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 2
102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 2
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 2
101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 2
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 2
101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims description 2
101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 2
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
102000006992 Interferon-alpha Human genes 0.000 claims description 2
108010047761 Interferon-alpha Proteins 0.000 claims description 2
102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
102000013691 Interleukin-17 Human genes 0.000 claims description 2
108050003558 Interleukin-17 Proteins 0.000 claims description 2
108010002386 Interleukin-3 Proteins 0.000 claims description 2
102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 2
102100034256 Mucin-1 Human genes 0.000 claims description 2
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
108060006580 PRAME Proteins 0.000 claims description 2
102000036673 PRAME Human genes 0.000 claims description 2
102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
230000010799 Receptor Interactions Effects 0.000 claims description 2
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 claims description 2
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 2
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
102000040856 WT1 Human genes 0.000 claims description 2
108700020467 WT1 Proteins 0.000 claims description 2
101150084041 WT1 gene Proteins 0.000 claims description 2
230000010252 chemokine signaling pathway Effects 0.000 claims description 2
230000018044 dehydration Effects 0.000 claims description 2
238000006297 dehydration reaction Methods 0.000 claims description 2
108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
102000006815 folate receptor Human genes 0.000 claims description 2
108020005243 folate receptor Proteins 0.000 claims description 2
229960005386 ipilimumab Drugs 0.000 claims description 2
230000003211 malignant effect Effects 0.000 claims description 2
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 2
229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
101150047061 tag-72 gene Proteins 0.000 claims description 2
229950007217 tremelimumab Drugs 0.000 claims description 2
201000009030 Carcinoma Diseases 0.000 claims 15
208000009956 adenocarcinoma Diseases 0.000 claims 8
208000037828 epithelial carcinoma Diseases 0.000 claims 4
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 4
208000029974 neurofibrosarcoma Diseases 0.000 claims 4
201000003076 Angiosarcoma Diseases 0.000 claims 3
201000008808 Fibrosarcoma Diseases 0.000 claims 3
206010018338 Glioma Diseases 0.000 claims 3
206010038038 rectal cancer Diseases 0.000 claims 3
206010041823 squamous cell carcinoma Diseases 0.000 claims 3
206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
206010006187 Breast cancer Diseases 0.000 claims 2
208000026310 Breast neoplasm Diseases 0.000 claims 2
208000032612 Glial tumor Diseases 0.000 claims 2
208000001258 Hemangiosarcoma Diseases 0.000 claims 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
201000004458 Myoma Diseases 0.000 claims 2
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 2
206010033128 Ovarian cancer Diseases 0.000 claims 2
208000015634 Rectal Neoplasms Diseases 0.000 claims 2
208000005718 Stomach Neoplasms Diseases 0.000 claims 2
201000010983 breast ductal carcinoma Diseases 0.000 claims 2
230000000112 colonic effect Effects 0.000 claims 2
210000002615 epidermis Anatomy 0.000 claims 2
206010017758 gastric cancer Diseases 0.000 claims 2
201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
201000004933 in situ carcinoma Diseases 0.000 claims 2
206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 2
201000005202 lung cancer Diseases 0.000 claims 2
201000001275 rectum cancer Diseases 0.000 claims 2
201000011549 stomach cancer Diseases 0.000 claims 2
208000010576 undifferentiated carcinoma Diseases 0.000 claims 2
GFZFAQOKWZGMQL-UHFFFAOYSA-N 3-[3,5-bis(trifluoromethyl)phenyl]-3-oxopropanenitrile Chemical compound FC(F)(F)C1=CC(C(=O)CC#N)=CC(C(F)(F)F)=C1 GFZFAQOKWZGMQL-UHFFFAOYSA-N 0.000 claims 1
206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
206010004146 Basal cell carcinoma Diseases 0.000 claims 1
206010004593 Bile duct cancer Diseases 0.000 claims 1
206010006143 Brain stem glioma Diseases 0.000 claims 1
102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
206010007275 Carcinoid tumour Diseases 0.000 claims 1
208000009458 Carcinoma in Situ Diseases 0.000 claims 1
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
208000005243 Chondrosarcoma Diseases 0.000 claims 1
208000006332 Choriocarcinoma Diseases 0.000 claims 1
208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
206010011732 Cyst Diseases 0.000 claims 1
206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims 1
206010059352 Desmoid tumour Diseases 0.000 claims 1
208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
208000006168 Ewing Sarcoma Diseases 0.000 claims 1
201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 claims 1
206010064147 Gastrointestinal inflammation Diseases 0.000 claims 1
206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
206010073069 Hepatic cancer Diseases 0.000 claims 1
101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
108010050904 Interferons Proteins 0.000 claims 1
102000014150 Interferons Human genes 0.000 claims 1
208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims 1
208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims 1
206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
206010073338 Optic glioma Diseases 0.000 claims 1
206010061328 Ovarian epithelial cancer Diseases 0.000 claims 1
206010061535 Ovarian neoplasm Diseases 0.000 claims 1
206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
208000006265 Renal cell carcinoma Diseases 0.000 claims 1
208000000453 Skin Neoplasms Diseases 0.000 claims 1
206010041067 Small cell lung cancer Diseases 0.000 claims 1
201000007180 bile duct carcinoma Diseases 0.000 claims 1
210000000481 breast Anatomy 0.000 claims 1
208000002458 carcinoid tumor Diseases 0.000 claims 1
201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
208000016154 cervical small cell carcinoma Diseases 0.000 claims 1
208000009060 clear cell adenocarcinoma Diseases 0.000 claims 1
PBKSAWGZZXKEBJ-UHFFFAOYSA-N cyclopenta-1,3-diene;4-cyclopenta-2,4-dien-1-ylphenol;iron(2+) Chemical compound [Fe+2].C=1C=C[CH-]C=1.C1=CC(O)=CC=C1[C-]1C=CC=C1 PBKSAWGZZXKEBJ-UHFFFAOYSA-N 0.000 claims 1
208000031513 cyst Diseases 0.000 claims 1
201000006827 desmoid tumor Diseases 0.000 claims 1
208000018529 duodenal adenocarcinoma Diseases 0.000 claims 1
201000005839 duodenum adenocarcinoma Diseases 0.000 claims 1
208000023965 endometrium neoplasm Diseases 0.000 claims 1
230000003511 endothelial effect Effects 0.000 claims 1
201000004101 esophageal cancer Diseases 0.000 claims 1
201000009593 extraosseous chondrosarcoma Diseases 0.000 claims 1
230000003352 fibrogenic effect Effects 0.000 claims 1
230000000762 glandular Effects 0.000 claims 1
231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
229940079322 interferon Drugs 0.000 claims 1
201000002313 intestinal cancer Diseases 0.000 claims 1
210000000244 kidney pelvis Anatomy 0.000 claims 1
208000003849 large cell carcinoma Diseases 0.000 claims 1
201000002250 liver carcinoma Diseases 0.000 claims 1
208000025036 lymphosarcoma Diseases 0.000 claims 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
201000001441 melanoma Diseases 0.000 claims 1
201000004058 mixed glioma Diseases 0.000 claims 1
208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims 1
208000008511 optic nerve glioma Diseases 0.000 claims 1
201000008968 osteosarcoma Diseases 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
229950010773 pidilizumab Drugs 0.000 claims 1
208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
210000002307 prostate Anatomy 0.000 claims 1
208000020615 rectal carcinoma Diseases 0.000 claims 1
208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
201000000849 skin cancer Diseases 0.000 claims 1
208000000649 small cell carcinoma Diseases 0.000 claims 1
208000000587 small cell lung carcinoma Diseases 0.000 claims 1
210000004500 stellate cell Anatomy 0.000 claims 1
230000002792 vascular Effects 0.000 claims 1
238000011282 treatment Methods 0.000 description 150
241000699670 Mus sp. Species 0.000 description 117
230000037449 immunogenic cell death Effects 0.000 description 109
230000006698 induction Effects 0.000 description 90
150000007523 nucleic acids Chemical class 0.000 description 86
102000014914 Carrier Proteins Human genes 0.000 description 83
108091008324 binding proteins Proteins 0.000 description 83
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 81
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 81
102000039446 nucleic acids Human genes 0.000 description 81
108020004707 nucleic acids Proteins 0.000 description 81
239000013598 vector Substances 0.000 description 68
238000010186 staining Methods 0.000 description 67
108090000765 processed proteins & peptides Proteins 0.000 description 64
102000004169 proteins and genes Human genes 0.000 description 63
235000018102 proteins Nutrition 0.000 description 61
102000004196 processed proteins & peptides Human genes 0.000 description 52
229920001184 polypeptide Polymers 0.000 description 44
239000000556 agonist Substances 0.000 description 43
235000001014 amino acid Nutrition 0.000 description 41
229940024606 amino acid Drugs 0.000 description 39
125000003275 alpha amino acid group Chemical group 0.000 description 36
150000001413 amino acids Chemical class 0.000 description 36
238000002595 magnetic resonance imaging Methods 0.000 description 36
238000011002 quantification Methods 0.000 description 36
241000713666 Lentivirus Species 0.000 description 34
208000015181 infectious disease Diseases 0.000 description 32
108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 31
238000012546 transfer Methods 0.000 description 31
239000000523 sample Substances 0.000 description 29
210000000952 spleen Anatomy 0.000 description 27
241000699666 Mus <mouse, genus> Species 0.000 description 26
208000037841 lung tumor Diseases 0.000 description 26
108020004414 DNA Proteins 0.000 description 25
238000003364 immunohistochemistry Methods 0.000 description 25
239000004615 ingredient Substances 0.000 description 25
241000700605 Viruses Species 0.000 description 23
238000002648 combination therapy Methods 0.000 description 23
108060001084 Luciferase Proteins 0.000 description 22
239000005089 Luciferase Substances 0.000 description 22
230000035772 mutation Effects 0.000 description 21
102000037982 Immune checkpoint proteins Human genes 0.000 description 19
108091008036 Immune checkpoint proteins Proteins 0.000 description 19
230000008859 change Effects 0.000 description 19
238000003384 imaging method Methods 0.000 description 19
229940126546 immune checkpoint molecule Drugs 0.000 description 18
150000001875 compounds Chemical class 0.000 description 17
208000035475 disorder Diseases 0.000 description 17
230000004936 stimulating effect Effects 0.000 description 17
229910052717 sulfur Inorganic materials 0.000 description 17
230000003442 weekly effect Effects 0.000 description 17
238000010241 blood sampling Methods 0.000 description 16
230000006870 function Effects 0.000 description 16
210000003714 granulocyte Anatomy 0.000 description 16
238000009169 immunotherapy Methods 0.000 description 16
230000009545 invasion Effects 0.000 description 16
210000001616 monocyte Anatomy 0.000 description 16
238000011084 recovery Methods 0.000 description 16
238000005303 weighing Methods 0.000 description 16
230000000903 blocking effect Effects 0.000 description 15
230000008595 infiltration Effects 0.000 description 15
238000001764 infiltration Methods 0.000 description 15
230000002601 intratumoral effect Effects 0.000 description 15
230000001926 lymphatic effect Effects 0.000 description 15
239000013603 viral vector Substances 0.000 description 15
238000000684 flow cytometry Methods 0.000 description 14
108020001507 fusion proteins Proteins 0.000 description 14
102000037865 fusion proteins Human genes 0.000 description 14
239000003550 marker Substances 0.000 description 14
210000005015 mediastinal lymph node Anatomy 0.000 description 14
238000006467 substitution reaction Methods 0.000 description 14
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
238000012217 deletion Methods 0.000 description 13
230000037430 deletion Effects 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
108010042407 Endonucleases Proteins 0.000 description 12
238000003556 assay Methods 0.000 description 12
238000003209 gene knockout Methods 0.000 description 12
239000002773 nucleotide Substances 0.000 description 12
125000003729 nucleotide group Chemical group 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
230000002759 chromosomal effect Effects 0.000 description 11
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
230000003463 hyperproliferative effect Effects 0.000 description 10
210000000987 immune system Anatomy 0.000 description 10
230000002401 inhibitory effect Effects 0.000 description 10
108091079001 CRISPR RNA Proteins 0.000 description 9
102100031780 Endonuclease Human genes 0.000 description 9
101710163270 Nuclease Proteins 0.000 description 9
125000000539 amino acid group Chemical group 0.000 description 9
210000004443 dendritic cell Anatomy 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
108091033409 CRISPR Proteins 0.000 description 8
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 8
108060003951 Immunoglobulin Proteins 0.000 description 8
102100022338 Integrin alpha-M Human genes 0.000 description 8
102000049583 human ROR1 Human genes 0.000 description 8
102000018358 immunoglobulin Human genes 0.000 description 8
238000003780 insertion Methods 0.000 description 8
230000037431 insertion Effects 0.000 description 8
230000006780 non-homologous end joining Effects 0.000 description 8
102000007863 pattern recognition receptors Human genes 0.000 description 8
108010089193 pattern recognition receptors Proteins 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
230000008685 targeting Effects 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
102000017578 LAG3 Human genes 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
230000008901 benefit Effects 0.000 description 7
238000012512 characterization method Methods 0.000 description 7
230000005782 double-strand break Effects 0.000 description 7
102000015694 estrogen receptors Human genes 0.000 description 7
108010038795 estrogen receptors Proteins 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000002163 immunogen Effects 0.000 description 7
239000003446 ligand Substances 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
238000010361 transduction Methods 0.000 description 7
230000026683 transduction Effects 0.000 description 7
241001430294 unidentified retrovirus Species 0.000 description 7
108091026890 Coding region Proteins 0.000 description 6
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
230000004913 activation Effects 0.000 description 6
229940100198 alkylating agent Drugs 0.000 description 6
239000002168 alkylating agent Substances 0.000 description 6
229960004316 cisplatin Drugs 0.000 description 6
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
238000012239 gene modification Methods 0.000 description 6
230000005017 genetic modification Effects 0.000 description 6
235000013617 genetically modified food Nutrition 0.000 description 6
238000010362 genome editing Methods 0.000 description 6
239000000411 inducer Substances 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
238000001890 transfection Methods 0.000 description 6
102100027207 CD27 antigen Human genes 0.000 description 5
102000004533 Endonucleases Human genes 0.000 description 5
108020005004 Guide RNA Proteins 0.000 description 5
101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 5
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 5
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
206010035226 Plasma cell myeloma Diseases 0.000 description 5
229940079156 Proteasome inhibitor Drugs 0.000 description 5
239000012190 activator Substances 0.000 description 5
230000000735 allogeneic effect Effects 0.000 description 5
229940045799 anthracyclines and related substance Drugs 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
238000001574 biopsy Methods 0.000 description 5
229940097217 cardiac glycoside Drugs 0.000 description 5
239000002368 cardiac glycoside Substances 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
210000003958 hematopoietic stem cell Anatomy 0.000 description 5
229960000908 idarubicin Drugs 0.000 description 5
229920006008 lipopolysaccharide Polymers 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
229960001156 mitoxantrone Drugs 0.000 description 5
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 5
201000000050 myeloid neoplasm Diseases 0.000 description 5
210000000822 natural killer cell Anatomy 0.000 description 5
239000003207 proteasome inhibitor Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
241000894007 species Species 0.000 description 5
229930002534 steroid glycoside Natural products 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000013519 translation Methods 0.000 description 5
230000032258 transport Effects 0.000 description 5
241001529453 unidentified herpesvirus Species 0.000 description 5
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
108010006654 Bleomycin Proteins 0.000 description 4
102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 4
102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 description 4
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
102000011727 Caspases Human genes 0.000 description 4
108010076667 Caspases Proteins 0.000 description 4
230000004568 DNA-binding Effects 0.000 description 4
108010092160 Dactinomycin Proteins 0.000 description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 4
101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
102100033467 L-selectin Human genes 0.000 description 4
108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 description 4
108700019146 Transgenes Proteins 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229960001230 asparagine Drugs 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229960001561 bleomycin Drugs 0.000 description 4
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
229960001467 bortezomib Drugs 0.000 description 4
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
229960000975 daunorubicin Drugs 0.000 description 4
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000013461 design Methods 0.000 description 4
238000010494 dissociation reaction Methods 0.000 description 4
230000005593 dissociations Effects 0.000 description 4
229960004679 doxorubicin Drugs 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
230000036541 health Effects 0.000 description 4
230000003308 immunostimulating effect Effects 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000010354 integration Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
244000005700 microbiome Species 0.000 description 4
238000011275 oncology therapy Methods 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000002243 precursor Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000005855 radiation Effects 0.000 description 4
230000010076 replication Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
230000009466 transformation Effects 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
238000010354 CRISPR gene editing Methods 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
241000710198 Foot-and-mouth disease virus Species 0.000 description 3
241001663880 Gammaretrovirus Species 0.000 description 3
102100037907 High mobility group protein B1 Human genes 0.000 description 3
101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 3
101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 3
101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 3
102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
101150030213 Lag3 gene Proteins 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
102000012750 Membrane Glycoproteins Human genes 0.000 description 3
108010090054 Membrane Glycoproteins Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
108020004485 Nonsense Codon Proteins 0.000 description 3
102100024952 Protein CBFA2T1 Human genes 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 3
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
238000011467 adoptive cell therapy Methods 0.000 description 3
229960000473 altretamine Drugs 0.000 description 3
230000000340 anti-metabolite Effects 0.000 description 3
230000001028 anti-proliverative effect Effects 0.000 description 3
230000006023 anti-tumor response Effects 0.000 description 3
210000000612 antigen-presenting cell Anatomy 0.000 description 3
229940100197 antimetabolite Drugs 0.000 description 3
239000002256 antimetabolite Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
229960002092 busulfan Drugs 0.000 description 3
229960004562 carboplatin Drugs 0.000 description 3
230000030833 cell death Effects 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000010276 construction Methods 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
229960000640 dactinomycin Drugs 0.000 description 3
238000010586 diagram Methods 0.000 description 3
230000034431 double-strand break repair via homologous recombination Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
238000010195 expression analysis Methods 0.000 description 3
239000004052 folic acid antagonist Substances 0.000 description 3
230000009368 gene silencing by RNA Effects 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
231100000118 genetic alteration Toxicity 0.000 description 3
230000004077 genetic alteration Effects 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
238000004020 luminiscence type Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
229960004961 mechlorethamine Drugs 0.000 description 3
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
231100000782 microtubule inhibitor Toxicity 0.000 description 3
229960004857 mitomycin Drugs 0.000 description 3
230000037434 nonsense mutation Effects 0.000 description 3
244000309459 oncolytic virus Species 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
238000003068 pathway analysis Methods 0.000 description 3
238000002428 photodynamic therapy Methods 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
230000001124 posttranscriptional effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
230000007115 recruitment Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000008439 repair process Effects 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
150000008143 steroidal glycosides Chemical class 0.000 description 3
CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 3
IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical group CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
102000035160 transmembrane proteins Human genes 0.000 description 3
108091005703 transmembrane proteins Proteins 0.000 description 3
229960003048 vinblastine Drugs 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
239000011701 zinc Substances 0.000 description 3
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 description 2
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
229940126253 ADU-S100 Drugs 0.000 description 2
102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
229940121697 CD27 agonist Drugs 0.000 description 2
229940123205 CD28 agonist Drugs 0.000 description 2
229940123189 CD40 agonist Drugs 0.000 description 2
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010077544 Chromatin Proteins 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
101150082208 DIABLO gene Proteins 0.000 description 2
230000005778 DNA damage Effects 0.000 description 2
231100000277 DNA damage Toxicity 0.000 description 2
230000007018 DNA scission Effects 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
108090000331 Firefly luciferases Proteins 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 2
101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 description 2
101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
102000043131 MHC class II family Human genes 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108700011259 MicroRNAs Proteins 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000714177 Murine leukemia virus Species 0.000 description 2
101100038118 Mus musculus Ror1 gene Proteins 0.000 description 2
KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
240000007019 Oxalis corniculata Species 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
240000007643 Phytolacca americana Species 0.000 description 2
235000009074 Phytolacca americana Nutrition 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
108091005685 RIG-I-like receptors Proteins 0.000 description 2
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
OTJHLDXXJHAZTN-BYPYZUCNSA-N S-(2-boronoethyl)-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCCB(O)O OTJHLDXXJHAZTN-BYPYZUCNSA-N 0.000 description 2
101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000008235 Toll-Like Receptor 9 Human genes 0.000 description 2
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
102000002689 Toll-like receptor Human genes 0.000 description 2
108020000411 Toll-like receptor Proteins 0.000 description 2
102000008230 Toll-like receptor 3 Human genes 0.000 description 2
108010060885 Toll-like receptor 3 Proteins 0.000 description 2
102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
229940122803 Vinca alkaloid Drugs 0.000 description 2
101150024410 Xcl1 gene Proteins 0.000 description 2
108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
102000018162 alpha-Macroglobulins Human genes 0.000 description 2
108010091268 alpha-Macroglobulins Proteins 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000000074 antisense oligonucleotide Substances 0.000 description 2
238000012230 antisense oligonucleotides Methods 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
229940127093 camptothecin Drugs 0.000 description 2
229960005243 carmustine Drugs 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000003483 chromatin Anatomy 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
230000000139 costimulatory effect Effects 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
210000003515 double negative t cell Anatomy 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
229960001904 epirubicin Drugs 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
230000004927 fusion Effects 0.000 description 2
229960005277 gemcitabine Drugs 0.000 description 2
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000002706 hydrostatic effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000011532 immunohistochemical staining Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
229960004768 irinotecan Drugs 0.000 description 2
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
239000002679 microRNA Substances 0.000 description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
229950006344 nocodazole Drugs 0.000 description 2
238000012758 nuclear staining Methods 0.000 description 2
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
244000045947 parasite Species 0.000 description 2
239000002245 particle Substances 0.000 description 2
229960002340 pentostatin Drugs 0.000 description 2
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
229960003171 plicamycin Drugs 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
229960000624 procarbazine Drugs 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 2
239000012217 radiopharmaceutical Substances 0.000 description 2
229940121896 radiopharmaceutical Drugs 0.000 description 2
230000002799 radiopharmaceutical effect Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
229940126625 tavolimab Drugs 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
229960004964 temozolomide Drugs 0.000 description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
229960001278 teniposide Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229960001196 thiotepa Drugs 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
229960003087 tioguanine Drugs 0.000 description 2
229940044693 topoisomerase inhibitor Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000002463 transducing effect Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
229940121351 vopratelimab Drugs 0.000 description 2
MHVJRKBZMUDEEV-APQLOABGSA-N (+)-Pimaric acid Chemical class [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@](C=C)(C)C=C2CC1 MHVJRKBZMUDEEV-APQLOABGSA-N 0.000 description 1
MHVJRKBZMUDEEV-UHFFFAOYSA-N (-)-ent-pimara-8(14),15-dien-19-oic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)C=C1CC2 MHVJRKBZMUDEEV-UHFFFAOYSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
HFKKMXCOJQIYAH-YFKPBYRVSA-N (S)-2-amino-6-boronohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCB(O)O HFKKMXCOJQIYAH-YFKPBYRVSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
102000009346 Adenosine receptors Human genes 0.000 description 1
108050000203 Adenosine receptors Proteins 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
102000000412 Annexin Human genes 0.000 description 1
108050008874 Annexin Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
229940080328 Arginase inhibitor Drugs 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
229940125565 BMS-986016 Drugs 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
108090000342 C-Type Lectins Proteins 0.000 description 1
102000003930 C-Type Lectins Human genes 0.000 description 1
102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
238000011357 CAR T-cell therapy Methods 0.000 description 1
108010079458 CBLB502 Proteins 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
229940123169 Caspase inhibitor Drugs 0.000 description 1
102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
229940123587 Cell cycle inhibitor Drugs 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 1
102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
101710163595 Chaperone protein DnaK Proteins 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
108091028075 Circular RNA Proteins 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
108010051219 Cre recombinase Proteins 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Chemical class 0.000 description 1
102000003849 Cytochrome P450 Human genes 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
239000012624 DNA alkylating agent Substances 0.000 description 1
229940126161 DNA alkylating agent Drugs 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
CROUPKILZUPLQA-ITVSDQETSA-N Dehydrosoyasaponin I Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H](O[C@@H]([C@@H](O)[C@@H]2O)C(O)=O)O[C@@H]2[C@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@@]6(C)C(=O)CC(C)(C)C[C@H]6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)O[C@H](CO)[C@H](O)[C@@H]1O CROUPKILZUPLQA-ITVSDQETSA-N 0.000 description 1
CTQURVKMWHDOKO-UHFFFAOYSA-N Dehydrosoyasaponin I Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3C(O)C(O)C(OC3OC4CCC5(C)C(CCC6(C)C5CC=C7C8CC(C)(C)CC(=O)C8(C)CCC67C)C4(C)C=O)C(=O)O)C(O)C(O)C1O CTQURVKMWHDOKO-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000010772 Dog disease Diseases 0.000 description 1
102100025137 Early activation antigen CD69 Human genes 0.000 description 1
DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 1
101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 1
101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 1
101000889899 Enterobacteria phage T4 Intron-associated endonuclease 2 Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108091007413 Extracellular RNA Proteins 0.000 description 1
241000713800 Feline immunodeficiency virus Species 0.000 description 1
241000714165 Feline leukemia virus Species 0.000 description 1
241000714174 Feline sarcoma virus Species 0.000 description 1
241000282324 Felis Species 0.000 description 1
108010040721 Flagellin Proteins 0.000 description 1
241000710781 Flaviviridae Species 0.000 description 1
102100035233 Furin Human genes 0.000 description 1
108090001126 Furin Proteins 0.000 description 1
101710121810 Galectin-9 Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
108060005986 Granzyme Proteins 0.000 description 1
102000001398 Granzyme Human genes 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
101710113864 Heat shock protein 90 Proteins 0.000 description 1
102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 1
101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
101100273713 Homo sapiens CD2 gene Proteins 0.000 description 1
101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 description 1
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 1
101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010014726 Interferon Type I Proteins 0.000 description 1
102000002227 Interferon Type I Human genes 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102100039897 Interleukin-5 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
102000000585 Interleukin-9 Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
229940125563 LAG3 inhibitor Drugs 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
101710091439 Major capsid protein 1 Proteins 0.000 description 1
102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
SGDBTWWWUNNDEQ-UHFFFAOYSA-N Merphalan Chemical compound OC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-UHFFFAOYSA-N 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
229940122255 Microtubule inhibitor Drugs 0.000 description 1
108020005196 Mitochondrial DNA Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
108010006519 Molecular Chaperones Proteins 0.000 description 1
102000005431 Molecular Chaperones Human genes 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
101100330194 Mus musculus Cyren gene Proteins 0.000 description 1
101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
FQWRAVYMZULPNK-BYPYZUCNSA-N N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NO FQWRAVYMZULPNK-BYPYZUCNSA-N 0.000 description 1
102000012064 NLR Proteins Human genes 0.000 description 1
108091005686 NOD-like receptors Proteins 0.000 description 1
KOBHCUDVWOTEKO-VKHMYHEASA-N Nomega-hydroxy-nor-l-arginine Chemical compound OC(=O)[C@@H](N)CCNC(=N)NO KOBHCUDVWOTEKO-VKHMYHEASA-N 0.000 description 1
241000714209 Norwalk virus Species 0.000 description 1
108010064641 ONX 0912 Proteins 0.000 description 1
YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
239000012270 PD-1 inhibitor Substances 0.000 description 1
239000012668 PD-1-inhibitor Substances 0.000 description 1
239000012648 POLY-ICLC Substances 0.000 description 1
108091081548 Palindromic sequence Proteins 0.000 description 1
102000007497 Patched-2 Receptor Human genes 0.000 description 1
108010071083 Patched-2 Receptor Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
102100029740 Poliovirus receptor Human genes 0.000 description 1
229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108091030071 RNAI Proteins 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
241001632234 Senecavirus Species 0.000 description 1
241000287219 Serinus canaria Species 0.000 description 1
241001522306 Serinus serinus Species 0.000 description 1
108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 description 1
108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 1
102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000713675 Spumavirus Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
108091027544 Subgenomic mRNA Proteins 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
230000029662 T-helper 1 type immune response Effects 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
102100036407 Thioredoxin Human genes 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
108091028113 Trans-activating crRNA Proteins 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
102100039630 Transmembrane protein PVRIG Human genes 0.000 description 1
108010023649 Tripartite Motif Proteins Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
241000713325 Visna/maedi virus Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
229960003697 abatacept Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229930183665 actinomycin Natural products 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229940125364 angiotensin receptor blocker Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000002942 anti-growth Effects 0.000 description 1
230000002095 anti-migrative effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000004900 autophagic degradation Effects 0.000 description 1
KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960005347 belatacept Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 1
102000015736 beta 2-Microglobulin Human genes 0.000 description 1
108010081355 beta 2-Microglobulin Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229940108502 bicnu Drugs 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
230000009460 calcium influx Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000010325 cell repair pathway Effects 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
238000009172 cell transfer therapy Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000014564 chemokine production Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
229960003633 chlorzoxazone Drugs 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
229960003009 clopidogrel Drugs 0.000 description 1
238000004891 communication Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
210000005220 cytoplasmic tail Anatomy 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
125000002185 docetaxel anhydrous group Chemical group 0.000 description 1
235000020669 docosahexaenoic acid Nutrition 0.000 description 1
229940090949 docosahexaenoic acid Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229950010033 ebselen Drugs 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
229940056913 eftilagimod alfa Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
108010026638 endodeoxyribonuclease FokI Proteins 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
229950009493 entolimod Drugs 0.000 description 1
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
229950006370 epacadostat Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
231100000776 exotoxin Toxicity 0.000 description 1
239000002095 exotoxin Substances 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
229960000961 floxuridine Drugs 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
229940045109 genistein Drugs 0.000 description 1
235000006539 genistein Nutrition 0.000 description 1
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002337 glycosamines Chemical group 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000003668 hormone analog Substances 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
102000049262 human DEFB4A Human genes 0.000 description 1
102000045108 human EGFR Human genes 0.000 description 1
102000052073 human NGFR Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
229940121569 ieramilimab Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
229940044680 immune agonist Drugs 0.000 description 1
239000012651 immune agonist Substances 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000028557 immunoglobulin binding proteins Human genes 0.000 description 1
108091009323 immunoglobulin binding proteins Proteins 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000006057 immunotolerant effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
210000005061 intracellular organelle Anatomy 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960003648 ixazomib Drugs 0.000 description 1
MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 1
MBOMYENWWXQSNW-AWEZNQCLSA-N ixazomib citrate Chemical compound N([C@@H](CC(C)C)B1OC(CC(O)=O)(CC(O)=O)C(=O)O1)C(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MBOMYENWWXQSNW-AWEZNQCLSA-N 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
150000002669 lysines Chemical class 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229940124302 mTOR inhibitor Drugs 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
238000007726 management method Methods 0.000 description 1
229950002736 marizomib Drugs 0.000 description 1
230000013011 mating Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
102000027540 membrane-bound PRRs Human genes 0.000 description 1
108091008872 membrane-bound PRRs Proteins 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000004065 mitochondrial dysfunction Effects 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
210000003643 myeloid progenitor cell Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 1
RRTPWQXEERTRRK-UHFFFAOYSA-N n-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide Chemical compound C1=CC=CC2=C3N(OCCCCNC(=O)CCCCCCCCCCCCCCCCC)C(CCCC)=NC3=C(N)N=C21 RRTPWQXEERTRRK-UHFFFAOYSA-N 0.000 description 1
229940086322 navelbine Drugs 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229950007221 nedaplatin Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
229950005750 oprozomib Drugs 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
238000009931 pascalization Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229940121655 pd-1 inhibitor Drugs 0.000 description 1
229930192851 perforin Natural products 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
229950005566 picoplatin Drugs 0.000 description 1
IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
229960004403 pixantrone Drugs 0.000 description 1
PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229940115270 poly iclc Drugs 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000006555 post-translational control Effects 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
244000144977 poultry Species 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000861 pro-apoptotic effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
238000007420 radioactive assay Methods 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
229960005399 satraplatin Drugs 0.000 description 1
190014017285 satraplatin Chemical compound 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000004904 shortening Methods 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000029069 type 2 immune response Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
229960000653 valrubicin Drugs 0.000 description 1
ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
239000005412 xenoestrogen Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
229960002911 zonisamide Drugs 0.000 description 1

JP2020513340A 2017-09-06 2018-09-06 養子細胞治療を改善するための方法 Pending JP2020533289A (ja)